[Pharmacological and clinical profile of once weekly alendronate for the treatment of osteoporosis (Fosamac 35 mg/Bonalon 35 mg)].
Uchida
Shinji
S
shinji_uchida@merck.com
Azuma
Yoshiaki
Y
Taniguchi
Tadaaki
T
Arizono
Hironori
H
Shimizu
Takafumi
T
Okaniwa
Masahiko
M
Nakamura
Keisuke
K
Ohta
Tomohiro
T
D019386:Alendronate / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D000818:Animals; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D001862:Bone Resorption; D001842:Bone and Bones / Q000378:metabolism; D004311:Double-Blind Method; D004947:Esophagus / Q000187:drug effects; D005260:Female; D006801:Humans; D008798:Mevalonic Acid / Q000378:metabolism; D010010:Osteoclasts / Q000187:drug effects / Q000378:metabolism; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic
D050071:Bone Density Conservation Agents; D008798:Mevalonic Acid; D019386:Alendronate